Table A2.
Dose Exposure for Subjects With Disease Control
| Subject No. | Cancer Type | Best Response | Durability of Response (cycles) | Assigned Dose Level (mg) | Dose Schedule | Exposure per Cycle (mg) |
|---|---|---|---|---|---|---|
| 301 | SCLC | SD | 4 | 10 | 14/21 | 140 |
| 317 | Carcinoid | SD | 6 | 130 | 14/21 | 1,820 |
| 320 | SCLC | SD | 2 | 130 | 14/21 | 1,820 |
| 331 | Carcinoid | SD | 8 | 325 | 14/21 | 4,550 |
| 332 | SCLC | SD | 2 | 425 | 14/21 | 5,950 |
| 335 | Carcinoid | SD | 2 | 325 | 14/21 | 4,550 |
| 338 | SCLC | PR | 35 | 425 | 14/21 | 5,950 |
| 348 | SCLC | SD | 2 | 225 | 21/21 | 4,725 |
| 353 | SCLC | SD | 17 | 325 | 21/21 | 6,825 |
Abbreviations: SCLC, small-cell lung cancer; SD, stable disease; PR, partial response.